PTPRC and neoplasm: CD45 has been analyzed less frequently than other TIL markers in HNSCC, but our results are in accordance with another study that suggests that CD45 expression could be a potential marker for tumor outcome in HNSCC patients [34] The finding that a high CD8/FoxP3 ratio was a near significant predictor of OS in OSCC also matches previous reports [23,[35], [36], [37]]